Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
Lei, Tianyao, Xu, Tianwei, Zhang, Niu, Zou, Xiaoteng, Kong, Ziyue, Wei, Chenchen, Wang, Zhaoxia
Published in Pharmacological research (01.10.2023)
Published in Pharmacological research (01.10.2023)
Get full text
Journal Article
Long noncoding RNA SNHG15: A promising target in human cancers
Zhang, Niu, Lei, Tianyao, Xu, Tianwei, Zou, Xiaoteng, Wang, Zhaoxia
Published in Frontiers in oncology (28.03.2023)
Published in Frontiers in oncology (28.03.2023)
Get full text
Journal Article
Long noncoding RNA SNHG17: a novel molecule in human cancers
Ma, Li, Gao, Jin, Zhang, Niu, Wang, Jiawei, Xu, Tianwei, Lei, Tianyao, Zou, Xiaoteng, Wei, Chenchen, Wang, Zhaoxia
Published in Cancer cell international (05.03.2022)
Published in Cancer cell international (05.03.2022)
Get full text
Journal Article
The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
Ren, Shengnan, Zhu, Ya, Wang, Siying, Zhang, Qinqiu, Zhang, Niu, Zou, Xiaoteng, Wei, Chenchen, Wang, Zhaoxia
Published in Acta biochimica et biophysica Sinica (25.11.2022)
Published in Acta biochimica et biophysica Sinica (25.11.2022)
Get full text
Journal Article